NVO
Novo Nordisk A/S
37.30$
-0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +20.8% | +26.2% | -14.8% | +8.4% | +4.9% | +11.0% | +5.9% | +43.4% | +38.1% | +11.1% | -1.5% | |
| – | -13.9% | +7.9% | -0.3% | +23.4% | +44.2% | +1.6% | +4.7% | +22.2% | +27.9% | +103.0% | +15.0% | |
| – | +19.1% | -16.7% | -20.7% | +41.8% | -12.3% | +126.7% | +26.4% | +48.0% | +39.6% | +6.5% | – | |
| – | -100.0% | +6,367,372.5% | -68.0% | +55.7% | +24.4% | +31.5% | +19.1% | +109.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | +44.3% | |
| – | +47.8% | +29.1% | +4.6% | +43.5% | -9.5% | +96.6% | -66.6% | +99.8% | +163.6% | +31.9% | +75.6% | |
| – | +195.4% | +11.3% | -3.2% | +83.8% | -4.7% | +94.9% | +40.9% | -21.2% | +76.1% | +193.7% | -38.6% | |
| – | +8.8% | +84.7% | -20.9% | +1.1% | +1.9% | +3.7% | +6.9% | +17.6% | +25.5% | +38.9% | +17.3% | |
| – | +17.2% | -12.4% | +11.9% | -7.6% | -1.5% | +9.9% | +15.4% | +23.9% | +24.2% | -32.6% | -93.1% | |
| – | – | +1,532,789.4% | +0.0% | +0.0% | -888.3% | – | +226.9% | -115.6% | -39.1% | – | -66.1% | |
| – | +13.4% | +29.2% | -8.2% | -3.3% | +2.8% | -9.1% | -20.9% | +103.2% | +21.9% | – | -425.2% | |
| – | -31.3% | +20.1% | -149.9% | – | – | – | – | – | -10.1% | -27.4% | +755.8% | |
| – | +16.5% | +25.6% | -18.8% | -1.0% | +10.4% | -16.0% | +59.4% | +34.7% | +9.2% | -0.5% | -58.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.